Evidence map›Paper›PMID 29046444›Full record

ArticleJournal of virology2018

Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals.

Francis Mwimanzi, Mako Toyoda, Macdonald Mahiti, Jaclyn K Mann, Jeffrey N Martin, David Bangsberg, Mark A Brockman, Philip Goulder, Frank Kirchhoff, Zabrina L Brumme and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Host-virus interaction and viral evasion.Cell biology international · 2021
    Review
  6. Article
  7. Concanamycin A counteracts HIV-1 Nef to enhance immune clearance of infected primary cells by cytotoxic T lymphocytes.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 6 countries.

Francis MwimanziCenter for AIDS Research, Kumamoto University, Kumamoto, Japan.
Mako ToyodaCenter for AIDS Research, Kumamoto University, Kumamoto, Japan.
Macdonald MahitiCenter for AIDS Research, Kumamoto University, Kumamoto, Japan.
Jaclyn K MannHIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, South Africa.
Jeffrey N MartinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
David BangsbergSchool of Public Health, Oregon Health and Science University-Portland State University, Portland, Oregon, USA.
Mark A BrockmanSimon Fraser University, Burnaby, BC, Canada.ORCID http://orcid.org/0000-0001-6432-1426
Philip GoulderDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom.
Frank KirchhoffInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Zabrina L BrummeSimon Fraser University, Burnaby, BC, Canada.
Thumbi Ndung'uHIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, South Africa.
Takamasa UenoCenter for AIDS Research, Kumamoto University, Kumamoto, Japan uenotaka@kumamoto-u.ac.jp.ORCID http://orcid.org/0000-0003-4852-4236
Kumamoto University · JPSimon Fraser University · CAPortland State University · USRagon Institute of MGH, MIT and Harvard · USUniversität Ulm · DEUniversity of California, San Francisco · USUniversity of KwaZulu-Natal · ZAUniversity of Oxford · GB

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
AIDS and Cancer Specimen Resource (ACSR)UM1CA181255 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jeffrey Michael Bethony, Anna Coghill · 2013 to 2026
$56.7M
TB PREVENTION AND HIV IN THE HOMELESS--AN INTERVENTIONR01MH054907 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BANGSBERG, DAVID ROY · 1995 to 2014
$20.7M
CIHR HOP-115700CIHR PJT-148621Howard Hughes Medical InstituteNCI NIH HHS UM1 CA181255NIAID NIH HHS P30 AI027763NIMH NIH HHS R01 MH054907
6 · The paper itself

Abstract

Patient-derived HIV-1 subtype B Nef clones downregulate HLA-A more efficiently than HLA-B. However, it remains unknown whether this property is common to Nef proteins across primate lentiviruses and how antiviral immune responses may be affected. We examined 263 Nef clones from diverse primate lentiviruses including different pandemic HIV-1 group M subtypes for their ability to downregulate major histocompatibility complex class A (MHC-A) and MHC-B from the cell surface. Though lentiviral Nef proteins differed markedly in their absolute MHC-A and MHC-B downregulation abilities, all lentiviral Nef lineages downregulated MHC-A, on average, 11 to 32% more efficiently than MHC-B. Nef genotype/phenotype analyses in a cohort of HIV-1 subtype C-infected patients (

Indexed as

AllelesCodonDown-RegulationHIV-1HIV InfectionsHLA-A AntigensHLA-B AntigensHumansImmune EvasionImmunity, CellularLentiviruses, PrimateMutagenesis, Site-Directednef Gene Products, Human Immunodeficiency VirusPhenotypeT-LymphocytesCodonHLA-A AntigensHLA-B Antigensnef Gene Products, Human Immunodeficiency VirusHLAhuman immunodeficiency virusimmune evasionlentivirusesNef

Identifiers

PMID29046444
PMCPMC5730772
OpenAlexW2766361906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.